Mumbai, Nov 9 (IANS): Pharmaceutical major Ranbaxy Laboratories Wednesday reported a net loss of Rs.464.6 crore for the quarter ended Sep 30. The company had posted a profit of Rs.308 crore in the like period of 2010-11.

The company said in a statement here: "Profitability below earnings before interest, tax, depreciation and amortization (EBITDA) line was impacted owing to the long dated derivative transactions entered into by the company in earlier years."

The pharma major's sales for the quarter under review grew by 8 percent at Rs.2,028 crore from Rs.1,880.9 crore in the corresponding quarter of the previous fiscal.

"Emerging markets contributed $262 million, accounting for 60 percent of total sales. Developed markets recorded $145 million of sales and contributed 33 percent to total sales for the company," the statement said.

In India, the company reported a sales growth of 6.46 percent at Rs.515.7 crore from Rs.484.4 crore in the like period of 2010-11.

"Consumer Healthcare contributed Rs.86.6 crore, while the acute therapy part of business was impacted by industry-wide slow-down in the anti-infective space," the statement added.

The company's chief executive and managing director Arun Sawhney said in a statement: "Ranbaxy's focus on long term improvement of its base business and margins has begun to reflect in the company's performance."

The company's scrip at the Bombay Stock Exchange (BSE) closed at Rs.475.40 -- down 4.31 percent.